Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Ebiomedicine|August 30, 2020
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanomaAnne Fröhlich, Judith Sirokay, Simon Fietz, et al.
Frontiers in Immunology|January 21, 2022
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular CytotoxicityMaryam Hejazi, Congcong Zhang, Sabrina B Bennstein, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Scientific Reports|September 27, 2024
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinomaMichael Praktiknjo, Ana S Pena Solano, Farsaneh Sadeghlar, et al.
Blood|October 2, 2014
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantationRichard F Schlenk, Sabine Kayser, Lars Bullinger, et al.
Blood|May 7, 2014
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patientsMichela Tassara, Konstanze Döhner, Peter Brossart, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow TransplantationKavita Raj, Diderik-Jan Eikema, Donal P McLornan, et al.
Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.
BMC Cancer|November 1, 2019
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer CenterMarie K Budde, Walther Kuhn, Mignon-Denise Keyver-Paik, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Pageof 27